What Do Doctors Think About Biosimilars?
•Descargar como PPTX, PDF•
18 recomendaciones•2,209 vistas
As the global biosimilars market opens up, what do physicians faced with choosing between prescribing a brand-name biologic or biosimilar think – and know?
Denunciar
Compartir
Denunciar
Compartir
Recomendados
Better Together: 2019 Patient Services Survey
Accenture Life Sciences survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations compared to those of pharma companies and whether integration of those services would improve the patient experience. Visit https://accntu.re/2Y9CGqw to learn more.
Better Together: 2019 Patient Services Survey - Country Results
Accenture Life Sciences survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations. Explore the unique differences by country. Visit https://accntu.re/2Y9CGqw to learn more.
Better Together 2019 Patient Services Survey - Condition Results
Accenture Life Sciences online survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations. Explore the unique differences by condition. Visit https://accntu.re/2Y9CGqw to learn more.
How hospitals can keep doctors happy
Keeping top-performing physicians happy is the key to a hospital's success. They enhance the reputation of your hospital and attract more patients. With physician engagement at an all-time low, hospitals need to find a solution—and fast.
Discover how an insight community can help you build better relationships with your physicians and drive better business decisions:
https://www.visioncritical.com/solutions/health-and-pharmaceuticals/
The Complete Guide to Wellness Software Development
Healthcare. It’s just one word, but it feels like over a hundred problems and potential solutions spun up like a spider web — benefits, cost savings and improvements are stuck together without being truly connected.
Thirteen common pitfalls in consumer health engagement final 04 11
The document outlines 13 common pitfalls in consumer health engagement. These include: not defining success metrics, limiting design based on company constraints rather than consumer experience, forgetting about health literacy, not understanding the entire consumer process, thinking you represent all consumers rather than understanding their diverse perspectives, creating generalized outreach rather than personalizing, assuming people are always logical, forgetting the incentives for consumers, not understanding local context, over-relying on surveys without controls, not using control groups in testing, not planning for programs to scale, and not integrating engagement across channels. The overall message is that effective consumer health programs require understanding the consumer perspective.
Oncologists' social networks
An update of earlier presentations on physicians' social networks, but with a focus on oncology, one of the most e-reliant specialities in medicine. First presented at Sales & Marketing for Oncology Therapeutics, Brussels, 16 March 2010.
How to respond to what healthcare professionals are telling us?
Between 25 June and 18 July 2014, Agnitio ran a survey to discover how well the industry is responding to healthcare professionals’ needs. The survey included an expert panel discussion and a questionnaire in which 192 professionals took part.
Recomendados
Better Together: 2019 Patient Services Survey
Accenture Life Sciences survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations compared to those of pharma companies and whether integration of those services would improve the patient experience. Visit https://accntu.re/2Y9CGqw to learn more.
Better Together: 2019 Patient Services Survey - Country Results
Accenture Life Sciences survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations. Explore the unique differences by country. Visit https://accntu.re/2Y9CGqw to learn more.
Better Together 2019 Patient Services Survey - Condition Results
Accenture Life Sciences online survey of 4,000 patients across four countries and three conditions reveals how patients use and value services from patient organizations. Explore the unique differences by condition. Visit https://accntu.re/2Y9CGqw to learn more.
How hospitals can keep doctors happy
Keeping top-performing physicians happy is the key to a hospital's success. They enhance the reputation of your hospital and attract more patients. With physician engagement at an all-time low, hospitals need to find a solution—and fast.
Discover how an insight community can help you build better relationships with your physicians and drive better business decisions:
https://www.visioncritical.com/solutions/health-and-pharmaceuticals/
The Complete Guide to Wellness Software Development
Healthcare. It’s just one word, but it feels like over a hundred problems and potential solutions spun up like a spider web — benefits, cost savings and improvements are stuck together without being truly connected.
Thirteen common pitfalls in consumer health engagement final 04 11
The document outlines 13 common pitfalls in consumer health engagement. These include: not defining success metrics, limiting design based on company constraints rather than consumer experience, forgetting about health literacy, not understanding the entire consumer process, thinking you represent all consumers rather than understanding their diverse perspectives, creating generalized outreach rather than personalizing, assuming people are always logical, forgetting the incentives for consumers, not understanding local context, over-relying on surveys without controls, not using control groups in testing, not planning for programs to scale, and not integrating engagement across channels. The overall message is that effective consumer health programs require understanding the consumer perspective.
Oncologists' social networks
An update of earlier presentations on physicians' social networks, but with a focus on oncology, one of the most e-reliant specialities in medicine. First presented at Sales & Marketing for Oncology Therapeutics, Brussels, 16 March 2010.
How to respond to what healthcare professionals are telling us?
Between 25 June and 18 July 2014, Agnitio ran a survey to discover how well the industry is responding to healthcare professionals’ needs. The survey included an expert panel discussion and a questionnaire in which 192 professionals took part.
Understanding Patient opinion leaders in social media
This presentation takes a deep dive into patient opinion leader behavior in social media. It also show cases ways to incubate social media leaders rather than hiring expensive POLs.
Smiles That Save Lives
This document discusses how supporting patients holistically across their healthcare journey can improve health outcomes and commercial success for pharmaceutical companies. It notes that patients often feel unprepared for appointments, miss diagnosis windows, and don't understand their conditions. Providing education, referrals, activation, and validating patients at every stage can help with timely treatment, brand performance, and reduced inflammations. Creating digital tools that facilitate cohesive, patient-driven experiences and connect patients to information and peers can engage patients and improve understanding and acceptance of treatments.
Reimbursing Chronic Care Management
CMS has finally made chronic care management is reimbursable. Learn how your PCMH and care coordination efforts can now be billed.
The Top Seven Analytics-Driven Approaches for Reducing Diagnostic Error and I...
From a wrong diagnosis to a delayed one, diagnostic error is a growing concern in the industry. Diagnostic error consequences are severe—they are responsible for 17 percent of preventable deaths (according to a Harvard Medical Practice study) and account for the highest portion of total payments (32.5 percent), according to a 1986-2010 analysis of malpractice claims. Patient safety depends heavily on getting the diagnosis right the first time.
Health systems know reducing diagnostic error to improve patient safety is a top priority, but knowing where to start is a challenge. Systems can start by implementing the top seven analytics-driven approaches for reducing diagnostic error:
Use KPA to Target Improvement Areas
Always Consider Delayed Diagnosis
Diagnose Earlier Using Data
Use the Choosing Wisely Initiative as a Guide
Understand Patient Populations Using Data
Collaborate with Improvement Teams
Include Patients and Their Families
Patient centric care
Patient-centric care focuses on involving patients in their own care through shared decision making and improved communication. It has been shown to lead to better health outcomes while reducing costs. To achieve patient-centric care, providers must center care around the patient experience, advocate for population health, and find more cost-effective ways of delivering services. New technologies like telehealth, mobile apps, and wearables can also help facilitate more patient-centric approaches.
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...Deloitte United States
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is a Medicare payment law intended to drive health care payment and delivery system reform for clinicians, health systems, Medicare, and other government and commercial payers. Deloitte’s 2016 Survey of US Physicians sought to shed light on physicians’ awareness of MACRA, their perspectives on its implications, and their attitudes and readiness for change. The survey found that many physicians are unaware of MACRA. Regardless of their awareness level, most physicians surveyed would have to change aspects of their practice to meet the law’s requirements and to do well under its incentives. Many physicians surveyed recognize they will need to bear increased financial risk (under MACRA and in general) and need support and resources to develop the capabilities do so. http://www.deloitte.com/us/macra?id=us:2sm:3ss:macra:eng:lshc:071216Improving statin adherence through interactive voice technology & barrier bre...
This document discusses using interactive voice response (IVR) technology to improve statin adherence through targeted communications. It summarizes a statin adherence program at Kaiser Permanente Riverside that used IVR reminder calls, a barrier survey, and mail order options. The program reached 88% of the target population and 71% heard messages. It found the main barriers to adherence were not knowing to refill, cost, and convenience issues. Targeted messaging increased adherence, with 27% of those initially not intending to refill doing so after barrier messages. The program demonstrated how data and continuous improvement can enhance IVR's ability to personalize outreach at scale.
Webchutney Digital Healthcare Report 2011
Webchutney is an award-winning digital marketing agency in India that works with leading companies to develop engaging online experiences that build relationships with consumers. It provides services such as online advertising, website design, mobile marketing, and social media for clients in various industries including Airtel, Microsoft, Unilever, and Samsung. Ranked as India's number one digital agency for two years, Webchutney has over 200 professionals across multiple offices committed to leading the interactive marketing industry.
Pega Consumer Report
This document summarizes the results of a survey of 2,018 US consumers conducted in late 2018/early 2019 on behalf of Pegasystems. The survey found:
- Most respondents agreed that feeling financially stable makes them more likely to focus on health and well-being, and that they have easy access to healthy food.
- Over half were open to sharing health data digitally with their doctor to improve outcomes, though over 1/5 were reluctant about virtual doctor appointments.
- Over 2/3 would switch doctors due to poor communication, and over half would use free nurse advice for health issues.
Pega Healthcare Report
The document summarizes the results of a survey of 214 decision makers in healthcare payers, providers, and pharmaceutical companies about their engagement programs.
Key findings include:
- Over 90% of respondents agree their organization enables access to healthy food and multiple communication channels for patients/members. However, pharmaceutical companies showed slightly lower rates of agreement.
- Respondents reported using a variety of channels like email, phone, web portals, and text messaging to connect with patients/members, doctor's offices, hospitals, insurance payers, and other organizations. Email and phone were the most commonly used channels.
- Large majorities also agreed their organizations provide personalized wellness programs, build care teams, and incent
Patient_Engagement_Whitepaper
This document discusses 5 elements of a successful patient engagement strategy:
1. Define your organization's vision for patient engagement.
2. Create a culture of engagement within the practice.
3. Employ the right technology and services like patient portals.
4. Empower patients to become collaborators in their care.
5. Continuously evaluate progress and be ready to adapt the strategy.
True patient engagement involves patients managing their own health, a practice culture that prioritizes engagement, and collaboration between patients and providers.
The State of Global Well-Being
The world is becoming easier to understand through numbers. They can tell us how much an individual makes in a country, how many people are in that country, and how long these people can expect to live on average. But what about the more subjective concepts? How do we measure and understand happiness? Success? Gallup-Healthway's Global Well-Being Index has broken it down to people’s perception of five key elements in their life.
www.twitter.com/stinsondesign
www. facebook.com/stinsondesign
www.stinsondesign.com
The Digital KOL 6.2015
The document discusses the rise of digital physician key opinion leaders (KOLs) as a new paradigm in healthcare. Digital KOLs are physician experts who are also leaders in social media and champions of patient engagement and digital tools. They serve as advisors to digital health companies, help design medical apps and mobile clinical trials, and disseminate health information via social media to both professionals and patients. The digital age requires a new approach from the pharmaceutical industry, and digital physician KOLs can help drive this transition by promoting digital interactions and partnerships.
Engaging the hard_to_engage_through_innovative_channels
A presentation from the Care Continuum Alliance (CCA) that I gave with Aetna 2 years ago. I found it posted online and decided to share it.
http://www.carecontinuumalliance.org/theforum11/Presentations/Engaging_the_Hard_to_Engage_Through_Innovative_Channels.pdf
Digital revolutionizing
While digital technologies are transforming many industries, traditional healthcare still has a long way to catch up.
Harnessing Population Health Management to Promote Quality Improvement in Hea...
Harnessing Population Health Management to Promote Quality Improvement in Hea...Queena Deschene, RCFE
- Population health management focuses on keeping populations healthy and managing the health of those with chronic conditions through risk stratification, care coordination, and patient engagement.
- Advances in mobile technology, analytics, and cognitive computing like IBM's Watson are enabling more proactive, personalized, and predictive care that is centered around the individual patient.
- As payment models shift from fee-for-service to value-based care, and consumers take a more active role in their health, organizations need to harness data and analytics to improve outcomes and lower costs through population health management approaches.Patient Engagement: MD Insights
Pathways to Patient Engagement is a webinar series designed to foster collaboration and discussion between all involved in the healthcare process.
During the first webinar we explored physician insights and found 40% of the primary care physicians surveyed were not participating in any patient engagement activities. Surprising for sure! Review the deck and to see the current 'state of the union' on patient engagement.
Manhattan research knowledge bite
Global Doctors habits. Manhattan research. Overview.
Russia is a leader in professional online communities usage.
COVID-19 Patient Confidence Study
The study found that patient confidence in visiting healthcare providers is increasing in May. The percentage of patients delaying appointments is at its lowest level. Most patients expect to resume regular in-office visits within the next 1-2 months. Comfort levels in visiting primary care physicians and specialists have also increased. The use of telemedicine has grown significantly during the pandemic with 30% of patients using it in the past 3 months. Over half of patients feel that some appointments can be replaced by telehealth.
The Power and Promise of Unstructured Patient Data
Unstructured search capabilities, superior natural language processing, and healthcare ontology capabilities will help distinguish the leading products information and data-driven decision making.
BIOLOGICALS VS BIOSIMILARS
This document discusses biologics and biosimilars. It begins by explaining that biologics are large protein molecules derived from living cells that are used to treat diseases. Examples include human growth hormone, insulin, and monoclonal antibodies. Biosimilars are similar but not generic versions of innovator biologic products. The document outlines key differences between biologics and small molecule drugs, challenges in developing biosimilar monoclonal antibodies, and regulatory guidelines for approving biosimilars from organizations like WHO. It also discusses benefits and concerns regarding the use of biosimilars.
19. Agnes Klein - Health Canada
19. Agnes Klein - Health CanadaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Biosimilars are complex biologic drugs that are similar but not identical to innovative biologic reference products. Several key points are made:
- Biosimilars are regulated differently than small molecule generics due to biologics' larger size and more complex manufacturing processes.
- While some regulators may designate a biosimilar as interchangeable, decisions on substitution are made separately at a national or state level.
- Health Canada does not declare any drug interchangeable and leaves substitution decisions to provinces, whereas the FDA may designate a biosimilar interchangeable if it is biosimilar and switching poses no greater risk to patients.
- Automatic substitution is not recommended and interchangeability requires specifically designed clinical trials for eachMás contenido relacionado
La actualidad más candente
Understanding Patient opinion leaders in social media
This presentation takes a deep dive into patient opinion leader behavior in social media. It also show cases ways to incubate social media leaders rather than hiring expensive POLs.
Smiles That Save Lives
This document discusses how supporting patients holistically across their healthcare journey can improve health outcomes and commercial success for pharmaceutical companies. It notes that patients often feel unprepared for appointments, miss diagnosis windows, and don't understand their conditions. Providing education, referrals, activation, and validating patients at every stage can help with timely treatment, brand performance, and reduced inflammations. Creating digital tools that facilitate cohesive, patient-driven experiences and connect patients to information and peers can engage patients and improve understanding and acceptance of treatments.
Reimbursing Chronic Care Management
CMS has finally made chronic care management is reimbursable. Learn how your PCMH and care coordination efforts can now be billed.
The Top Seven Analytics-Driven Approaches for Reducing Diagnostic Error and I...
From a wrong diagnosis to a delayed one, diagnostic error is a growing concern in the industry. Diagnostic error consequences are severe—they are responsible for 17 percent of preventable deaths (according to a Harvard Medical Practice study) and account for the highest portion of total payments (32.5 percent), according to a 1986-2010 analysis of malpractice claims. Patient safety depends heavily on getting the diagnosis right the first time.
Health systems know reducing diagnostic error to improve patient safety is a top priority, but knowing where to start is a challenge. Systems can start by implementing the top seven analytics-driven approaches for reducing diagnostic error:
Use KPA to Target Improvement Areas
Always Consider Delayed Diagnosis
Diagnose Earlier Using Data
Use the Choosing Wisely Initiative as a Guide
Understand Patient Populations Using Data
Collaborate with Improvement Teams
Include Patients and Their Families
Patient centric care
Patient-centric care focuses on involving patients in their own care through shared decision making and improved communication. It has been shown to lead to better health outcomes while reducing costs. To achieve patient-centric care, providers must center care around the patient experience, advocate for population health, and find more cost-effective ways of delivering services. New technologies like telehealth, mobile apps, and wearables can also help facilitate more patient-centric approaches.
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...Deloitte United States
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is a Medicare payment law intended to drive health care payment and delivery system reform for clinicians, health systems, Medicare, and other government and commercial payers. Deloitte’s 2016 Survey of US Physicians sought to shed light on physicians’ awareness of MACRA, their perspectives on its implications, and their attitudes and readiness for change. The survey found that many physicians are unaware of MACRA. Regardless of their awareness level, most physicians surveyed would have to change aspects of their practice to meet the law’s requirements and to do well under its incentives. Many physicians surveyed recognize they will need to bear increased financial risk (under MACRA and in general) and need support and resources to develop the capabilities do so. http://www.deloitte.com/us/macra?id=us:2sm:3ss:macra:eng:lshc:071216Improving statin adherence through interactive voice technology & barrier bre...
This document discusses using interactive voice response (IVR) technology to improve statin adherence through targeted communications. It summarizes a statin adherence program at Kaiser Permanente Riverside that used IVR reminder calls, a barrier survey, and mail order options. The program reached 88% of the target population and 71% heard messages. It found the main barriers to adherence were not knowing to refill, cost, and convenience issues. Targeted messaging increased adherence, with 27% of those initially not intending to refill doing so after barrier messages. The program demonstrated how data and continuous improvement can enhance IVR's ability to personalize outreach at scale.
Webchutney Digital Healthcare Report 2011
Webchutney is an award-winning digital marketing agency in India that works with leading companies to develop engaging online experiences that build relationships with consumers. It provides services such as online advertising, website design, mobile marketing, and social media for clients in various industries including Airtel, Microsoft, Unilever, and Samsung. Ranked as India's number one digital agency for two years, Webchutney has over 200 professionals across multiple offices committed to leading the interactive marketing industry.
Pega Consumer Report
This document summarizes the results of a survey of 2,018 US consumers conducted in late 2018/early 2019 on behalf of Pegasystems. The survey found:
- Most respondents agreed that feeling financially stable makes them more likely to focus on health and well-being, and that they have easy access to healthy food.
- Over half were open to sharing health data digitally with their doctor to improve outcomes, though over 1/5 were reluctant about virtual doctor appointments.
- Over 2/3 would switch doctors due to poor communication, and over half would use free nurse advice for health issues.
Pega Healthcare Report
The document summarizes the results of a survey of 214 decision makers in healthcare payers, providers, and pharmaceutical companies about their engagement programs.
Key findings include:
- Over 90% of respondents agree their organization enables access to healthy food and multiple communication channels for patients/members. However, pharmaceutical companies showed slightly lower rates of agreement.
- Respondents reported using a variety of channels like email, phone, web portals, and text messaging to connect with patients/members, doctor's offices, hospitals, insurance payers, and other organizations. Email and phone were the most commonly used channels.
- Large majorities also agreed their organizations provide personalized wellness programs, build care teams, and incent
Patient_Engagement_Whitepaper
This document discusses 5 elements of a successful patient engagement strategy:
1. Define your organization's vision for patient engagement.
2. Create a culture of engagement within the practice.
3. Employ the right technology and services like patient portals.
4. Empower patients to become collaborators in their care.
5. Continuously evaluate progress and be ready to adapt the strategy.
True patient engagement involves patients managing their own health, a practice culture that prioritizes engagement, and collaboration between patients and providers.
The State of Global Well-Being
The world is becoming easier to understand through numbers. They can tell us how much an individual makes in a country, how many people are in that country, and how long these people can expect to live on average. But what about the more subjective concepts? How do we measure and understand happiness? Success? Gallup-Healthway's Global Well-Being Index has broken it down to people’s perception of five key elements in their life.
www.twitter.com/stinsondesign
www. facebook.com/stinsondesign
www.stinsondesign.com
The Digital KOL 6.2015
The document discusses the rise of digital physician key opinion leaders (KOLs) as a new paradigm in healthcare. Digital KOLs are physician experts who are also leaders in social media and champions of patient engagement and digital tools. They serve as advisors to digital health companies, help design medical apps and mobile clinical trials, and disseminate health information via social media to both professionals and patients. The digital age requires a new approach from the pharmaceutical industry, and digital physician KOLs can help drive this transition by promoting digital interactions and partnerships.
Engaging the hard_to_engage_through_innovative_channels
A presentation from the Care Continuum Alliance (CCA) that I gave with Aetna 2 years ago. I found it posted online and decided to share it.
http://www.carecontinuumalliance.org/theforum11/Presentations/Engaging_the_Hard_to_Engage_Through_Innovative_Channels.pdf
Digital revolutionizing
While digital technologies are transforming many industries, traditional healthcare still has a long way to catch up.
Harnessing Population Health Management to Promote Quality Improvement in Hea...
Harnessing Population Health Management to Promote Quality Improvement in Hea...Queena Deschene, RCFE
- Population health management focuses on keeping populations healthy and managing the health of those with chronic conditions through risk stratification, care coordination, and patient engagement.
- Advances in mobile technology, analytics, and cognitive computing like IBM's Watson are enabling more proactive, personalized, and predictive care that is centered around the individual patient.
- As payment models shift from fee-for-service to value-based care, and consumers take a more active role in their health, organizations need to harness data and analytics to improve outcomes and lower costs through population health management approaches.Patient Engagement: MD Insights
Pathways to Patient Engagement is a webinar series designed to foster collaboration and discussion between all involved in the healthcare process.
During the first webinar we explored physician insights and found 40% of the primary care physicians surveyed were not participating in any patient engagement activities. Surprising for sure! Review the deck and to see the current 'state of the union' on patient engagement.
Manhattan research knowledge bite
Global Doctors habits. Manhattan research. Overview.
Russia is a leader in professional online communities usage.
COVID-19 Patient Confidence Study
The study found that patient confidence in visiting healthcare providers is increasing in May. The percentage of patients delaying appointments is at its lowest level. Most patients expect to resume regular in-office visits within the next 1-2 months. Comfort levels in visiting primary care physicians and specialists have also increased. The use of telemedicine has grown significantly during the pandemic with 30% of patients using it in the past 3 months. Over half of patients feel that some appointments can be replaced by telehealth.
The Power and Promise of Unstructured Patient Data
Unstructured search capabilities, superior natural language processing, and healthcare ontology capabilities will help distinguish the leading products information and data-driven decision making.
La actualidad más candente (20)
Understanding Patient opinion leaders in social media
Understanding Patient opinion leaders in social media
The Top Seven Analytics-Driven Approaches for Reducing Diagnostic Error and I...
The Top Seven Analytics-Driven Approaches for Reducing Diagnostic Error and I...
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...
2016 Survey of US Physicians: Physician awareness, perspectives, and readines...
Improving statin adherence through interactive voice technology & barrier bre...
Improving statin adherence through interactive voice technology & barrier bre...
Engaging the hard_to_engage_through_innovative_channels
Engaging the hard_to_engage_through_innovative_channels
Harnessing Population Health Management to Promote Quality Improvement in Hea...
Harnessing Population Health Management to Promote Quality Improvement in Hea...
The Power and Promise of Unstructured Patient Data
The Power and Promise of Unstructured Patient Data
Destacado
BIOLOGICALS VS BIOSIMILARS
This document discusses biologics and biosimilars. It begins by explaining that biologics are large protein molecules derived from living cells that are used to treat diseases. Examples include human growth hormone, insulin, and monoclonal antibodies. Biosimilars are similar but not generic versions of innovator biologic products. The document outlines key differences between biologics and small molecule drugs, challenges in developing biosimilar monoclonal antibodies, and regulatory guidelines for approving biosimilars from organizations like WHO. It also discusses benefits and concerns regarding the use of biosimilars.
19. Agnes Klein - Health Canada
19. Agnes Klein - Health CanadaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Biosimilars are complex biologic drugs that are similar but not identical to innovative biologic reference products. Several key points are made:
- Biosimilars are regulated differently than small molecule generics due to biologics' larger size and more complex manufacturing processes.
- While some regulators may designate a biosimilar as interchangeable, decisions on substitution are made separately at a national or state level.
- Health Canada does not declare any drug interchangeable and leaves substitution decisions to provinces, whereas the FDA may designate a biosimilar interchangeable if it is biosimilar and switching poses no greater risk to patients.
- Automatic substitution is not recommended and interchangeability requires specifically designed clinical trials for each29. Prof. Sergey Tulyandin - Russian Scientific Oncology N.N. Blokhin Center
29. Prof. Sergey Tulyandin - Russian Scientific Oncology N.N. Blokhin CenterInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“Clinical aspects of Interchangeability, substitution and therapeutic switch of Biological Medicinal Products. From the Medical Community Point of View”
Provides an overview of the concerns around interchangeability and automatic substitution from the perspective of the physicians and the patientsmbbs ims msu
Mediated transport involves integral membrane proteins called transporters that facilitate the passage of molecules across membranes. There are two main types: facilitated diffusion, which moves molecules down their concentration gradient without energy, and active transport, which moves molecules against their gradient by using energy. Primary active transport directly uses ATP to pump ions like sodium and potassium, while secondary active transport uses ion gradients established by primary transport to move other molecules.
Class newer routes of drug delivery
This document discusses various drug delivery systems including:
1. Delayed and extended release systems which maintain therapeutic drug levels over time through enteric coating or matrix devices.
2. Site-specific systems like ocuserts for eye delivery or intrauterine devices for contraception.
3. Targeted drug carriers including liposomes, nanoparticles, and ligand-mediated systems using antibodies for diseases.
4. Rate-controlled systems that use diffusion, dissolution, or electrical currents to regulate drug release over time including transdermal patches.
5. Implantable systems for localized delivery through stents, microchips, or engineered tissues.
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
MATÉRIOVIGILANCE : Actualités
Par Sébastien Renard
COVIDIEN France SAS
Membrane transporters and drug response
Membrane transporters play an important role in drug absorption, distribution, and elimination. There are two main types of membrane transport proteins - channels and carriers. Channels passively transport ions and molecules via protein-lined pores, while carriers actively transport substances against concentration gradients using energy from ATP or ion gradients. Important carrier families include ABC transporters like P-gp and MRP, which pump various drugs and toxins out of cells, and SLC transporters like OATP, OCT, and MATE, which transport organic ions and molecules into and out of cells. Variations in membrane transporters can significantly impact drug pharmacokinetics, pharmacodynamics, and adverse drug responses. Further research is still needed to fully understand
Newer drug delivery systems
Drug delivery systems has undergone major modification in the recent past . With the advent of nanomedicines and liposomes , drug delivery systems has taken a huge leap towards targeted, carrier mediated and sustained release drug delivery.
Transporters as targets for drugs
This document presents an overview of transporters as targets for drugs. Transporters are membrane proteins that control the movement of drugs across biological barriers through various transport mechanisms. There are two main types of transporters - ATP-binding cassette (ABC) transporters and solute carrier (SLC) transporters. ABC transporters use ATP hydrolysis to actively transport substrates while SLC transporters use ion gradients to facilitate transport. Transporters play important roles in pharmacokinetic and pharmacodynamic pathways but can also contribute to drug resistance. Targeting transporters offers opportunities to modulate drug absorption, distribution, and resistance.
Pharmacogenomics
This document provides an overview of pharmacogenomics. It defines pharmacogenomics as the study of how genetic variations influence individual drug responses. It discusses how single nucleotide polymorphisms (SNPs) can alter drug metabolism and response. Examples are provided of genes like G6PD, TPMT, CYP2D6 and CYP2C9 that influence drug toxicity and efficacy. Benefits of pharmacogenomics include more powerful and safer drugs through personalized treatment based on an individual's genetic profile. Ethical concerns around privacy, discrimination, and drug availability are also discussed.
newer drug delivery systems
Dr. Manjeeta Gupta of the Department of Pharmacology at MIMER Medical College gave a presentation on newer drug delivery systems. The presentation covered various oral, transdermal, implantable, inhalation and injectable drug delivery technologies including osmotic systems, hydrodynamic systems, gastroretentive systems, transdermal patches, microneedle patches, drug-eluting stents, ocular inserts, insulin pens and pumps, nanoparticle delivery, and potential future technologies such as long-term biodegradable films for controlled drug release over months or years. The goal was to provide targeted and controlled delivery to improve drug bioavailability and patient compliance.
9 Karin Heidenreich - Novartis
9 Karin Heidenreich - NovartisInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document provides an overview of biosimilars and their development process according to international guidance. It begins with definitions of biosimilars and their differences compared to generic small molecule drugs. It then describes the two key steps in biosimilar development: 1) Developing a highly similar product through extensive analytical comparison to the reference product, and 2) Confirming biosimilarity through a targeted clinical program. It reviews guidelines from the WHO, EMA, and FDA on evaluating biosimilarity and the need for analytical, nonclinical and clinical comparisons. The document aims to explain the rigorous process of demonstrating biosimilarity that biosimilar developers must undergo to obtain regulatory approval.Medical Devices Postmarket Surveillance 14 jul13
This document discusses post-market surveillance requirements for medical devices under new European Medical Device Regulation proposals. It outlines various options for post-market surveillance, including utilizing existing vigilance systems, conducting literature reviews, implementing registries to collect clinical experience from device users, and conducting randomized controlled studies. While randomized controlled studies provide the strongest evidence, registries are more cost-effective. The document concludes that post-market surveillance will be more stringent and controlled under new regulations, and manufacturers should institute systematic procedures to collect experience from devices and apply necessary corrective actions.
schedule y of drugs and cosmetic acts
This document provides an overview of Schedule Y, which establishes requirements and guidelines for conducting clinical trials and obtaining permission to import or manufacture new drugs in India. Schedule Y aims to frame guidelines for clinical research in line with global standards. It outlines application procedures, ethics committee requirements, pre-clinical and clinical data to be submitted, protocol elements, and other rules to ensure safety and efficacy of investigational products. The objectives of Schedule Y are to regulate clinical trials and new drugs in India according to current scenarios and integrate the country into global drug development while improving clinical trial quality.
Smart Drug Delivery Systems
The presentation captures the IP activity along with the key players in the smart drug delivery system industry. The presentation also captures the distribution of patents across the world. The IP information, competitor activity and the technology classification are also included. Prior art problems and their respective solutions given in different patents are captured in addition to the taxonomy nodes (technology breakdown classification). Product analysis is done for seven products.
Newer drug delivery methods
The document discusses novel drug delivery systems. It begins with an overview of conventional drug delivery routes and their limitations. It then outlines the need for and goals of newer drug delivery modalities, which aim to control drug absorption, distribution, metabolism, and elimination. Several novel delivery routes are described in detail, including oral, sublingual, inhalation, transdermal, intranasal, and targeted delivery. Polymer-based delivery systems such as microspheres, nanoparticles, and intelligent delivery are also discussed. The document concludes by noting that advanced delivery technologies are playing an increasingly important role in improving drug safety, efficacy, and patient experience.
Different types of Drug Transporters in body By Anubhav Singh M.pharm 1st year
The document discusses the different mechanisms by which drugs can pass through biological barriers to reach their site of action. It describes transcellular transport, where drugs pass through cells via passive diffusion, carrier-mediated processes, or active transport. It also discusses paracellular transport between cell junctions. The main mechanisms of transcellular transport are described in detail, including passive diffusion, carrier-mediated transport, ion-pair transport, pore transport, and active transport via primary and secondary mechanisms. Vesicular transport is also summarized as a mechanism for larger molecules and particles.
Fixed dose combination products – rationality, status in india, development i...
The development of FDCs is becoming increasingly
important from a public health perspective.
•They are being used in the treatment of a wide range of
conditions and are particularly useful in the management of
human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS), malaria and tuberculosis, which are
considered to be the foremost infectious disease threats in the world today.
Drug transporters
This document discusses drug transporters and their role in drug absorption, distribution, metabolism and excretion. It covers the main types of transporters including ABC transporters like P-glycoprotein and SLC transporters. It describes how transporters regulate the movement of drugs across membranes in organs like the intestine, liver and kidneys. It also discusses how overexpression of transporters like P-glycoprotein can lead to multidrug resistance and the various approaches used to overcome resistance, such as inhibitors of transporter activity.
Schedule y, mk sharma
The document outlines a presentation on Schedule Y, which regulates clinical trials in India. It discusses the history of drug regulation in India, the key provisions of Schedule Y, and recent amendments made to Schedule Y. Some of the major changes include new definitions for clinical trials and new drugs, as well as additional regulation for special patient populations and post-marketing surveillance. The presentation provides an overview of Schedule Y and the rules governing clinical research in India.
Destacado (20)
29. Prof. Sergey Tulyandin - Russian Scientific Oncology N.N. Blokhin Center
29. Prof. Sergey Tulyandin - Russian Scientific Oncology N.N. Blokhin Center
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
Different types of Drug Transporters in body By Anubhav Singh M.pharm 1st year
Different types of Drug Transporters in body By Anubhav Singh M.pharm 1st year
Fixed dose combination products – rationality, status in india, development i...
Fixed dose combination products – rationality, status in india, development i...
Similar a What Do Doctors Think About Biosimilars?
Michael reilly toronto nov19presentation final
The document summarizes a presentation given by Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines (ASBM), about biosimilars and challenges in bringing them to patients. Some key points:
- Biosimilars provide increased treatment options and potential cost savings compared to reference biologics, but developing and approving biosimilars faces more challenges than generic drugs due to biologics' larger and more complex molecular structure.
- Physician confidence and acceptance is important for biosimilar use, but indication extrapolation and lack of long-term clinical data are concerns that could limit adoption.
- Through surveys of physicians worldwide, ASBM is providing data on physician perspectives to regulators
Biosimilar Development EPTM 2015
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
4440642.ppt
This document provides an overview of biologics and biosimilars. It defines biologics as complex medications made from living cells that treat diseases in novel ways. Biosimilars are highly similar but not identical copies of biologics that are approved through an abbreviated pathway. The FDA will determine standards for interchangeability and require rigorous testing to ensure biosimilars are safely effective for each condition and patient group. Important issues for patients include ensuring safety, transparency, and choice in biologic treatment.
Navigant: The Birth of An Orphan Biosimilar Market
1. Biosimilar pathways have been established, many biologic patents will expire by 2025 exposing $33 billion in orphan drug sales to potential biosimilar competition. However, no true orphan biosimilars have reached the market yet due to challenges like rare disease patient recruitment for clinical trials.
2. Over the next decade, several monoclonal antibody orphan drugs will lose exclusivity including Soliris, Fabrazyme, and Pulmozyme. The first orphan biosimilar, Omnitrope for growth hormone deficiency, achieved 15% market share with a 40% price cut compared to the originator.
3. Regulators may consider relaxing clinical trial requirements for orphan biosimilars given small patient populations,
Biosimilars Pfizer symposium - Derick Mitchell - Nov 12th 2016
This document discusses biosimilars from the perspective of Irish patients. It finds that patient awareness and understanding of biosimilars is currently low in Ireland. Patients are most concerned about the safety of biosimilars compared to their concerns about effectiveness. While some patient-friendly information exists on biosimilars, patients report that it is often of poor quality or not widely available. The document emphasizes that patient involvement is important in any decisions made by doctors to switch patients from existing biologic treatments to biosimilar alternatives. More comprehensive and understandable information is still needed to help patients properly assess and understand biosimilars.
BioPharma Dealmakers_September 2015
Neuroscience is poised for increased deal activity after a period of setbacks. Advances in clinical trial design, imaging, and biomarkers are driving interest in neuroscience drugs. Venture funding and licensing deals in neurology and psychiatry totaled billions from 2005-2014, though M&A activity was lower. Recent large neuroscience acquisitions by companies like Celgene, Teva, and Biogen have sparked renewed enthusiasm. Experts predict precision medicine approaches will increase dealmaking as neurological diseases are further subtyped genetically.
Biosimilars Presentation - Health Canada
Presentation about Biosimilars on Save Your Skin Foundation webinar, January 19, 2018. This is presentation #1 of 3 in the webinar: 1. Health Canada 2. CADTH 3. Louise Binder, Save Your Skin Fdn.
Pharmacovigilance Risk Management for Biosimilars
This paper focuses on pharmacovigilance (PV) and risk management for biosimilars, the issues and challenges faced in monitoring their safety and possible solutions.
The Basic Facts About Biosimilars
In order to promote the uptake of biosimilars across the U.S., stakeholders must be informed about the basic science of these important medicines. Created out of the Biosimilars Forum's Biosimilars Roundtable (formerly the Biosimilars Forum Stakeholder Workshop group), this two page document incorporates feedback from nearly 40 stakeholder groups, from patient advocacy organizations to physician and payer groups, and presents the basic knowledge that all stakeholders need to know about the safety and efficacy of biosimilars, including answers to common myths about them.
9th Biosimilars Conference Brochure
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
9th Biosimilars (2011) Pp
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
Probiotics and prebiotics nrgastro.2014.66
The document presents the conclusions of an expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss definitions and appropriate use of the term "probiotic".
The panel reaffirmed the FAO/WHO definition of probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". The panel clarified inconsistencies between previous FAO/WHO reports and advanced the definition to account for scientific progress.
The panel concluded that certain health effects, such as supporting a healthy digestive tract and gut microbiota, can be reasonably expected from probiotic genera including Bifidobacterium and Lactobacillus. However
Biosimilars. Unpacking Complex Issues
This document discusses biosimilars, which are biologic drugs that are similar but not identical to already approved biologic drugs (reference biologics). It provides background on biologics and biosimilars, including that biosimilars take longer and cost less to develop than original biologics. Several regulatory issues for biosimilars are also discussed, such as naming, substitution, approval of indications, and reimbursement. The US recently approved its first biosimilar, but still lags behind Europe in approving and using biosimilars.
Botanicals 2021
This document discusses the growing botanical ingredients market. Some key points:
- Botanical ingredients are seeing renewed interest in Western markets as their health benefits become better understood. The global herbal medicines market was valued at $84.5 billion in 2019 and is projected to reach $411.2 billion by 2026.
- Younger consumers are particularly interested in botanicals and are driving demand. They seek products that are ethically sourced and organic.
- Ensuring quality and authenticity of botanical ingredients is challenging due to risks of adulteration, issues with certain ingredients becoming scarce, and lack of traceability in the supply chain. Advanced analytical techniques and blockchain are helping to address these problems
PodCase on biomedical engineering ethics
The podcast discusses the importance of considering ethics in biomedical engineering design decisions. It interviews Brigham Buhler on his perspective from 15 years of experience in the medical device and pharmaceutical industries. Buhler explains that biomedical engineers must consider how their designs impact patients' health and safety, as well as other stakeholders like doctors and regulators. The podcast highlights examples like artificial hearts and powered surgical tools that required addressing ethical issues around patient well-being and informed consent.
Biosimilars 2020
The present slide focuses on the applications and different uses of biosimilars along with the basic difference in between biosimilars and bioequivalence.
SMi Group's Biosimilars & Biobetters conference
This document summarizes an upcoming conference on biosimilars and biobetters to be held in London from September 29-30, 2014. The conference will include presentations and discussions on accelerating biosimilar drug development, regulatory pathways for biosimilars in Europe and the US, proving biosimilarity to reference products, and perceptions of biosimilars among doctors, patients, and payers in Europe. Attendees can also participate in two interactive workshops on biosimilar regulations and the commercial potential of biosimilars. Various industry experts will speak at the event to provide insights on this emerging field.
How the biologics landscape is evolving
1) As biologic drug sales increase, manufacturers are developing biosimilars and biobetters to maximize returns and benefit patients. Biosimilars may lower costs through competition, while biobetters aim to improve existing drugs.
2) Biosimilars are not identical to original biologics due to complex manufacturing processes, but can be approved through clinical trials demonstrating similarity. Biosimilars may save 10-35% of originator costs in Europe.
3) The US represents a major market opportunity but has not approved a regulatory pathway. Widespread biosimilar use depends on generating physician and patient confidence in quality and safety.
P Morgon_AJBiologics_World Vaccine Congress_2015 11_vFinal
Improving global healthcare and wellbeing requires addressing major challenges with vaccines and immunization acceptance. Key challenges include maintaining high vaccination rates without targeted diseases, overcoming vaccine fatigue, and dealing with misinformation that reduces trust. The path forward is promoting education on how vaccines comply with Islamic law while working to develop vaccines free of animal components through defined manufacturing processes. Addressing pressures around affordability, supply reliability, and demonstrating value are also important for immunization strategies and vaccine development.
Probiotics Infographic
Probiotic-fortified food & beverage market opportunities
Probiotics are live microorganisms, or “friendly bacteria,” similar to organisms that occur naturally in the digestive tract. These good bacteria have been clinically shown to support digestive and immune health, and have been linked to other emerging benefits.Here some facts about probiotics
Similar a What Do Doctors Think About Biosimilars? (20)
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar Market
Biosimilars Pfizer symposium - Derick Mitchell - Nov 12th 2016
Biosimilars Pfizer symposium - Derick Mitchell - Nov 12th 2016
P Morgon_AJBiologics_World Vaccine Congress_2015 11_vFinal
P Morgon_AJBiologics_World Vaccine Congress_2015 11_vFinal
Más de Small World Social
5 Upcoming Biosimilar Events You Don't Want to Miss
This document lists and provides details on 6 upcoming biosimilar events to attend, including dates and locations. Events include the Annual Biosimilars Summit in Berlin from June 11-12 focusing on biosimilar development strategies, the Bio International Convention in Philadelphia from June 15-18 covering biologics development and marketing issues, and the Biosimilar Global Congress 2015 Europe in London from September 28-30 addressing development to marketing of biosimilars.
Timeline of Biosimilars Pathways
The biosimilars frontier is still a fairly new market, but its regulatory beginnings can be traced back to the early 2000s, with Europe, Asia and Australia among the early adopters. See the attached document for a look at the global progress of biosimilars.
Get the latest on Biosimilars at https://www.smallworldsocial.com/biolink/
Curated resources updated daily.
Biosimilars 101
Each classification of drugs are unique. Learn how each are unique in their own way.
Conventional drugs, generics, biologics, and biosimilars are very different from one another. Each type of drug or product differs in structure, cost, characteristics, and development.
Get the latest on Biosimilars at https://www.smallworldsocial.com/biolink/
Curated resources updated daily.
Social Media Workshop
Social media is rapidly changing education and school environments, from students’ educational experiences to its use as a communication and information sharing tool for the education profession.
Australia has always been one of the fastest growing early adopter markets for new platforms and technologies. Coupled with the National Broadband Network (NBN) rollout, we will see even faster adoption and use. The NBN will provide enhanced infrastructure for delivering rich multimedia experiences and cloud-hosted applications in education. Over the next five years, the use of tablet devices like the iPad will become the norm and the desktop computer will disappear.
Understanding what the future will look like from a technology perspective is key to being able to develop the skills to maximise the opportunities it offers. The skills needed for teachers, students and parents in technology are quickly changing. Social media is at the forefront of this, with use and time spent in Australia online increasing significantly every year.
Understanding how to collect and share information and observe appropriate online etiquette in safe and secure ways are important concerns for educators, especially with the rapid uptake of social media. The aim of this workshop is to provide a picture of Australia’s current online usage and behaviour, outline broad international trends and their application in education and provide the opportunity to develop a safe and practical understanding of social media technologies that would be valuable in professional practice in education.
The Complexities of Social Media, kids and the Classroom
This document provides an overview and summary of a presentation on social media, kids, and the classroom. It discusses trends in social media usage among teachers and students in Australia. It also covers workshops on using Twitter, Tumblr, and the rise of the iPad in education. Australian statistics show high usage of social networks and time spent on blogs. Teachers' usage of YouTube, email and Wikipedia is presented. International trends point to the impacts of mobile devices, infrastructure changes, and crowd-sourced curriculum content. The workshops demonstrate how to use Twitter and Tumblr, their features, and educational applications. The implications of tablets like the iPad in the classroom are also examined.
Social Media and Social Networking
What's social media and what are the key trends in Australia?
This presentation covers basic definitions, key trends and examples of social media, including a case study on how the Colorado Springs Police Department (USA) has utilised social media.
Social Media for Law Enforcement Agencies
In this presentation we look at how law enforcement agencies around the world are using Social Media for Predictive, Proactive and Investigative reasons. We look at some best practice examples around the world and explored the role Social Media played in major world events like the UK Riots.
Presented by Kathy Phelan and Kanella Gougousis for the Australian Government Attorney-General's Department.
Memory Retention: iPad vs Print
With desktops diminishing and tablets becoming king, how will education be affected?
Is learning on tablets like the iPad better than old fashion pens and paper?
Who will win the battle in the classroom, Digital or Print?
Is your council Government 2.0 ready?
The document summarizes a presentation given to the Fairfield City Council Managers about using social media. It discusses how social media is used widely, provides examples of how some local governments and cities use social media platforms like Facebook and Twitter to engage with residents. The presentation covered statistics on social media usage, examples of case studies of other cities' social media use, and trends in internal social media use. It aimed to demonstrate how social media could be better utilized by the Fairfield City Council to engage with the community.
Overcoming the camel's hump with digital literacy: how Web 2.0 is changing ed...
The document summarizes a presentation given by Kathy Phelan from the Social Media Education Group to the Office of the Board of Studies NSW on May 4th, 2011. The presentation covered topics like the biggest impacts of technology, mobile devices, and content in 2011; big ideas for education including digital literacy; online education and crowd-sourced curriculum; overcoming challenges with digital literacy; the impact of social media on health and well-being; challenges of mobile devices; and the importance of being present offline. The presentation provided an overview of trends in web 2.0 and social media and their implications for education leaders.
Más de Small World Social (10)
5 Upcoming Biosimilar Events You Don't Want to Miss
5 Upcoming Biosimilar Events You Don't Want to Miss
The Complexities of Social Media, kids and the Classroom
The Complexities of Social Media, kids and the Classroom
Overcoming the camel's hump with digital literacy: how Web 2.0 is changing ed...
Overcoming the camel's hump with digital literacy: how Web 2.0 is changing ed...
Último
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
Monopoly PCD Pharma Franchise in Tripura
Our company incorporates various drug formulations covering pharma tablets, syrups, capsules, gels, sachets, ointments, creams, injectables.
Top massage center in ajman chandrima Spa
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Top Rated Massage Center In Ajman Chandrima Spa
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.Bath patient Fundamental of Nursing.pptx
This is presentation about how to bath a patient.
It is a fundamental of nursing.
CCSN_June_06 2024_jones. Cancer Rehabpptx
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
practical guide of obesityfinal hyper1د حاتم البيطار القمة اكاديمي 0120238902...
https://www.facebook.com/drhatemnutritiondiploma01005684344/
https://www.facebook.com/hospitaldrhatem/
📞 01202389028
📞 01005684344
#دحاتم_البيطار
https://64a832848a05c.site123.me/
https://64a9fcd1e98aa.site123.me/
#دكتور_حاتم_البيطار
#دحاتم_البيطار
#timodentist
#drhatem_elbitar
#محاضر_طبي
#مكافحة_العدوي
#الزمالة_المصرية
#دكتور_اسنان
#الهرم_الغذائي
#ادارة_المستشفيات
#أقوي_اعتماد_في_مصر
#الغذاء_الصحي
#دبلومة_التغذية
#الغذاء
#دحاتم_البيطار
#الغذاء_والتغذية
📞01005684344
💬 واتس 01202389028
#دكتور_حاتم_البيطار
#دحاتم_البيطار
#timodentist
hatem elbitar
مكافحة العدوي
ادارة المستشفيات
الزمالة المصرية
دكتور اسنان
الهرم الغذائي
ادارة المستشفيات
الغذاء الصحي
دبلومة التغذية
الغذاء
البيطار استشاري
slides
الغذاء والتغذية
📞01005684344
💬 واتس 01202389028
Dr Hatem ElBitar
د حاتم البيطار
أستشاري وجراح أسنان
زميل الزمالة المصرية
محاضر ادارة المستشفيات ومكافحة العدوى
01005684344
#دحاتم_البيطار
http://bit.ly/2xzMIlo
https://64a832848a05c.site123.me/
https://64a9fcd1e98aa.site123.me/
https://daalacademy.com/instructor/drhatemelbitar/
一比一原版(USF毕业证)旧金山大学毕业证如何办理
USF毕业证offer【微信95270640】《旧金山大学毕业证购买》《如何办理USF毕业证旧金山大学文凭学历》Q微信95270640实体公司，专业可靠，办理毕业证办美国成绩单,做加拿大文凭学历认证,办新西兰学位证，学位证书是什么?《制作旧金山大学毕业证多少钱》《USF学历证书丢了怎么办理》办澳洲文凭认证，办留信网认证（网上可查，实体公司，专业可靠）
专业为留学生办理旧金山大学旧金山大学硕士学位证成绩单【100%存档可查】留学全套申请材料办理。本公司承诺所有毕业证成绩单成品全部按照学校原版工艺对照一比一制作和学校一样的羊皮纸张保证您证书的质量！
如果你回国在学历认证方面有以下难题请联系我们我们将竭诚为你解决认证瓶颈
1所有材料真实但资料不全无法提供完全齐整的原件。【如：成绩单丶毕业证丶回国证明等材料中有遗失的。】
2获得真实的国外最终学历学位但国外本科学历就读经历存在问题或缺陷。【如：国外本科是教育部不承认的或者是联合办学项目教育部没有备案的或者外本科没有正常毕业的。】
3学分转移联合办学等情况复杂不知道怎么整理材料的。时间紧迫自己不清楚递交流程的。
如果你是以上情况之一请联系我们我们将在第一时间内给你免费咨询相关信息。我们将帮助你整理认证所需的各种材料.帮你解决国外学历认证难题。
国外旧金山大学旧金山大学硕士学位证成绩单办理方法：
1客户提供办理信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询旧金山大学旧金山大学硕士学位证成绩单）；
2开始安排制作旧金山大学毕业证成绩单电子图；
3旧金山大学毕业证成绩单电子版做好以后发送给您确认；
4旧金山大学毕业证成绩单电子版您确认信息无误之后安排制作成品；
5旧金山大学成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）。头贼脑的倒也逗人喜爱日上三竿时山娃总爱窜进自家瓜棚里跟小伙伴们坐着聊天聊着聊着便忍不住往瓜田里逡巡一番抱起一只硕大的西瓜用石刀劈开抑或用拳头砸开每人抱起一大块就啃啃得满嘴满脸猴屁股般的红艳大家一个劲地指着对方吃吃地笑瓜裂得古怪奇形怪状却丝毫不影响瓜味甜丝丝的满嘴生津遍地都是瓜横七竖八的活像掷满了一地的大石块摘走二三只爷爷是断然发现不了的即便发现爷爷也不恼反而教山娃辨认孰熟孰嫩孰甜孰淡名义上是护瓜吃
COLOUR CODING IN THE PERIOPERATIVE NURSING PRACTICE.
COLOUR CODING IN THE PERIOPERATIVE ENVIRONMENT HAS COME TO STAY ,SOME SENCE OF HUMOUR WILL BE APPRECIATED AT THE RIGHT TIME BY THE PATIENT AND OTHER SURGICAL TEAM MEMBERS.
ilide.info-assessment-of-renal-and-urinary-tract-function-pr_1aae1860e4cff0a4...
Assessment of Renal and Urinary Tract Function
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
FACIAL NERVE
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
Surface guided deep inspiration breath hold (SG-DIBH) in ultra-hypofractionat...
Cynthia Aristei
Professor
University of Perugia and Perugia General Hospital
Italy
The Importance of Black Women Understanding the Chemicals in Their Personal C...
Certain chemicals, such as phthalates and parabens, can disrupt the body's hormones and have significant effects on health. According to data, hormone-related health issues such as uterine fibroids, infertility, early puberty and more aggressive forms of breast and endometrial cancers disproportionately affect Black women. Our guest speaker, Jasmine A. McDonald, PhD, an Assistant Professor in the Department of Epidemiology at Columbia University in New York City, discusses the scientific reasons why Black women should pay attention to specific chemicals in their personal care products, like hair care, and ways to minimize their exposure.
National Rural Health Mission(NRHM).pptx
This document describes the NRHM Scheme, its goals, objectives, components, and new initiatives.
Sexual Disorders.gender identity disorderspptx
Gender identity disorder, paraphilias , sexual dysfunction
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx enhances healthcare by educating patients and ensuring effective medication management in a complex, evolving landscape.
Último (20)
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
practical guide of obesityfinal hyper1د حاتم البيطار القمة اكاديمي 0120238902...
practical guide of obesityfinal hyper1د حاتم البيطار القمة اكاديمي 0120238902...
COLOUR CODING IN THE PERIOPERATIVE NURSING PRACTICE.
COLOUR CODING IN THE PERIOPERATIVE NURSING PRACTICE.
ilide.info-assessment-of-renal-and-urinary-tract-function-pr_1aae1860e4cff0a4...
ilide.info-assessment-of-renal-and-urinary-tract-function-pr_1aae1860e4cff0a4...
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
Surface guided deep inspiration breath hold (SG-DIBH) in ultra-hypofractionat...
Surface guided deep inspiration breath hold (SG-DIBH) in ultra-hypofractionat...
The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and Engagement
What Do Doctors Think About Biosimilars?
- 1. What Do Doctors Think About Biosimilars? Powered by Small World Social www.biolink.us
- 2. In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologics medicines labeling. Powered by Small World Social www.biolink.us
- 3. The web-based survey was conducted before the FDA approved Zarxio, the first biosimilar in the US, and sought the view of dermatologists, endocrinologists, oncologists, nephrologists, neurologists and rheumatologists. It found… Powered by Small World Social www.biolink.us
- 4. Powered by Small World Social considered it important for a biosimilar’s product label to clearly indicate that it is a biosimilar. 90% of correspondents 4Biolink.us
- 5. Powered by Small World Social it important for the biosimilar label to include the biosimilar sponsor’s analytical data demonstrating its analytical similarity to the reference product 82% thought 5Biolink.us
- 6. Powered by Small World Social It important that the biosimilar label includes the clinical data, if any, submitted to the FDA by the sponsor again demonstrating that it is highly similar to the reference product 83% thought 6Biolink.us
- 7. Powered by Small World Social It important that the label explicitly state that the specific indications or conditions of use approved for the originator product that are not approved for the biosimilar product 79% found 7Biolink.us
- 8. In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines. Powered by Small World Social www.biolink.us
- 9. The survey highlighted the lack of awareness about biosimilars amongst prescribing specialist physicians and the need for further education. It found… Powered by Small World Social www.biolink.us
- 10. Powered by Small World Social said they are ‘familiar’ with biosimilars, but only have a basic understanding 54% of respondents 10Biolink.us
- 11. Powered by Small World Social were unable to define biosimilars 20% of the physicians 11Biolink.us
- 12. Powered by Small World Social had never heard of biosimilars 4% of respondents 12Biolink.us
- 13. Powered by Small World Social were ‘very familiar’, with a complete understanding of biosimilars 22% of the physicians 13Biolink.us
- 14. Meanwhile, a study conducted by the Tufts Center of the Study of Drug Development, at Tufts University in Boston, found that… Powered by Small World Social www.biolink.us
- 15. Powered by Small World Social While the majority of physicians, 70%, surveyed said they would be likely to prescribe biosimilars to a new patient, the overall lack of familiarity with the new products among specialist physicians could slow the uptake of biosimilars in the U.S. 15Biolink.us
- 16. Powered by Small World Social www.biolink.us Want to read more about biosimilars? Visit: https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world